Answers are grounded in this paper and cite their sources.
Many ophthalmic diseases progress over years, creating a practical limitation for preclinical drug development. Existing models address this problem by inducing disease-associated phenotypes over much shorter periods. Optic nerve crush, sodium iodate injury and microbead-induced ocular hypertension each provide useful experimental models [ 1 , 2 , 3 ], but each reproduces a defined component of disease through an experimentally imposed insult. The resulting phenotype may therefore differ from the sequence of molecular events occurring in chronic human disease.
No takes yet. Share an insight, caveat, or question.
Waisberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: